Context Therapeutics Email Format
Biotechnology ResearchPennsylvania, United States11-50 Employees
Context Therapeutics Inc. is a biopharmaceutical company in the biotechnology research industry focused on developing T cell engaging bispecific antibodies for solid tumors. The company is developing an innovative portfolio of TCE bispecific therapeutics, including CTIM-76 (Claudin 6 x CD3), CT-95 (Mesothelin x CD3), and CT-202 (Nectin-4 x CD3). It is headquartered in Philadelphia at 2001 Market Street Suite 3915 Unit 15, Philadelphia, Pennsylvania 19103. Context Therapeutics trades on Nasdaq under CNTX and employs 11-50 people. The company has announced participation in the AACR Annual Meeting 2026 with a poster presentation, reflecting ongoing engagement with the scientific community.